Market Research Logo

Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)

Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)

Pneumonia is a lung infection that causes inflammatory condition in one or both lungs. It affects small air sacs known as alveoli by filing them with fluid or pus, making a person difficult to breathe. It can be classified into community-acquired pneumonia and hospital-acquired pneumonia. Hospital acquired pneumonia can be further classified into healthcare associated pneumonia and ventilator associated pneumonia. A person suffering from pneumonia can experience problems like fever along with chills, cough with pus or phlegm, shortness of breath, pain in chest while breath in or coughing and lower than normal body temperature, rapid heartbeats, ongoing nausea or vomiting and decline in energy levels.

The U.S. is expected to be the first region to start selling pneumonia drugs in pipeline and later on, penetration of pneumonia drugs would occur in Europe. The U.S. and Europe have high prevalence of severe forms of multiple drug resistance (MDR) organism which would result into a high demand for pneumonia drugs in future.

The global pneumonia market is expected to grow in future with growing ageing population, increasing pharmaceutical R&D spending, increasing healthcare expenditure, accelerating economic growth, growing children population and rise in multiple drug resistance (MDR) organisms. Key trends of this market include progressing drug under pipeline, innovation in treatment options and increased preference towards combination therapy. However, there are some factors which can hinder growth of the market including stringent regulations and entry of generic drugs.

The report “Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan Plc, The Medicines Company and Nabriva Therapeutics.


1. Market Overview
1.1 Pneumonia
Table 1: Classification of Pneumonia
1.2 Causes
1.3 Symptoms and Diagnosis
1.4 Treatment
2. Global Pneumonia Market Analysis
2.1 Pneumonia Market
2.1.1 Global Lefamulin Drug Revenue Forecast
Table 2: Global Lefamulin Drug Revenue Forecast (2019-2025)
2.1.2 Global ASN100 Drug Revenue Forecast
Table 3: Global ASN100 Drug Revenue Forecast (2021-2025)
3. Regional Markets
3.1 The U.S.
3.1.1 The U.S. CAP Patient Population Forecast
Table 4: The U.S. CAP Patient Population Forecast (2017-2022)
3.1.2 The U.S. CAP Patient Population by Category
Table 5: The U.S. CAP Patient Population by Category (2017)
3.1.3 The U.S. CAP Outpatient Population Forecast
Table 6: The U.S. CAP Outpatient Population Forecast (2017-2022)
3.1.4 The U.S. CAP Hospital Patient Population Forecast
Table 7: The U.S. CAP Hospital Population Forecast (2017-2022)
3.1.5 The U.S. HAP/VAP Population Forecast
Table 8: The U.S. HAP/VAP Population Forecast (2022-2025)
3.1.6 The U.S. Lefamulin Drug Revenue Forecast by Category
Table 9: The U.S. Lefamulin Drug Revenue Forecast by Category (2019-2025)
3.1.7 The U.S. Lefamulin Drug Revenue Forecast by Patient Type for CAP
Table 10: The U.S. Lefamulin Drug Revenue Forecast by Patient Type for CAP (2019-2025)
3.1.8 The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP
The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP (2022-2025)
3.1.9 The U.S. ASN100 Drug Revenue Forecast for VAP
Table 12: The U.S. ASN100 Drug Revenue Forecast for VAP (2021-2025)
3.2 Europe
3.2.1 Europe CAP Patient Population Forecast
Table 13: Europe CAP Patient Population Forecast (2017-2022)
3.2.2 Europe CAP Patient Population by Category
Table 14: Europe CAP Patient Population by Category (2017)
3.2.3 Europe CAP Hospital Patient Population by Category
Table 15: Europe CAP Hospital Patient Population Forecast (2017-2022)
3.2.4 Europe CAP Outpatient Population Forecast
Table 16: Europe CAP Outpatient Population Forecast (2017-2022)
3.2.5 Europe VAP Patient Population Forecast
Table 17: Europe VAP Patient Population Forecast (2021-2025)
3.2.6 Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP
Table 18: Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP (2021-2025)
3.2.7 Europe ASN100 Drug Revenue Forecast for VAP
Table 19: Europe ASN100 Drug Revenue Forecast for VAP (2022-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Ageing Population
Table 20: Global Ageing Population (2012-2017)
4.1.2 Increasing Pharmaceutical R&D Spending
Table 21: Global Pharmaceutical R&D Spending (2013-2017)
4.1.3 Increasing Healthcare Expenditure
Table 22: Global Healthcare Expenditure (2012-2017)
4.1.4 Accelerating Economic Growth
Table 23: Global GDP Per Capita (2012-2017)
4.1.5 Growing Children Population
Table 24: Global Children Population (2012-2017)
4.1.6 Rise in Multiple Drug Resistance (MDR) Organisms
4.2 Key Trends & Developments
4.2.1 Progressing Drugs Under Pipeline
Table 25: Drugs under Development for Pneumonia (2017)
4.2.2 Innovation in Treatment Methods
4.2.3 Increased Preference Towards Combination Therapy
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Entry of Generic Drugs
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
Table 26: Global Pneumonia Market Key Players - Revenue Comparison (2016)
5.1.2 Market Cap Comparison of Key Players
Table 27: Global Pneumonia Market Key Players - Market Cap Comparison (2016)
6. Company Profiles
6.1 Nabriva Therapeutics
6.1.1 Business Overview
6.1.2 Financial Overview
Table 28: Nabriva Therapeutics Net Revenue and Net Income (Loss) (2013-2016)
6.1.3 Business Strategies
Table 29: Nabriva Therapeutics Research and Development Expenditure (2014-2016)
6.2 Merck & Co., Inc.
6.2.1 Business Overview
Table 30: Merck & Co., Inc. Revenue Share by Segments (2016)
6.2.2 Financial Overview
Table 31: Merck & Co., Inc. Net Revenue and Net Income (2012-2016)
6.2.3 Business Strategies
Table 32: Merck & Co. Research and Development Expenditure (2014-2016)
6.3 Allergan Plc
6.3.1 Business Overview
Table 33: Allergan Plc Revenue Share by Segments (2016)
6.3.2 Financial Overview
Table 34: Allergan Plc Net Revenue and Net Income (2012-2016)
6.3.3 Business Strategies
Table 35: Allergan Plc Research and Development Expenditure (2014-2016)
6.4 The Medicines Company
6.4.1 Business Overview
Table 37: The Medicines Company Revenue Share by Products (2016)
6.4.2 Financial Overview
Table 38: The Medicines Company Net Revenue and Net Income (Loss) (2012-2016)
6.4.3 Business Strategies
Table 39: The Medicines Company Research and Development Expenditure (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report